MA-TRAX-RETAIL
11.3.2024 22:26:34 CET | Business Wire | Press release
Trax Retail, the data and technology company digitizing the physical world of retail, today announces the appointment of Gary Laben as its chief executive officer. As Trax’s CEO, Laben will lead the tech-enabled and data-driven retail platform through its next phase of growth, focusing on building upon its innovative and industry-leading solutions for CPG manufacturers, retailers, and shoppers.
“As the pioneer and leader in retail innovation and execution, Trax has a transformational opportunity to capitalize on new data streams and technology,” said Laben. “I am thrilled to join the team and look forward to enhancing our current solutions and developing new capabilities for our core sector and beyond.”
Laben has three decades of global experience in information services and technology, with a particular focus on strategic planning, product development, operational excellence, and business transformation. In 2018, as Research Now’s CEO, he led the successful merger with SSI to create Dynata, the world’s largest provider of fully-permissioned first-party data, where he most recently served as CEO. During his six-year tenure, Laben tripled revenue and quadrupled EBITDA, in collaboration with 5,500 employees spanning 40+ countries. He conceived and executed the strategy to diversify company offerings beyond market research into media and advertising, resulting in new revenue streams that now account for more than 25 percent of Dynata’s revenue. Through mergers, strategic acquisitions, and investments, Laben cemented Dynata as not only the industry’s largest player, but as the provider of the highest quality products, the best customer service, and the most innovative product offerings.
“Gary’s background is the ideal combination of technology-driven information services experience, proven leadership, and innovative market and product development,” said Joel Bar-El, Executive Chairman of Trax. “With our continued momentum in the global retail sector, we’re investing in a leader who will elevate Trax to the next level. ”
Before joining Dynata, Laben was Global Chief Data Officer at Wunderman and CEO of KBM Group, where he grew revenue 10X and operating profit 15X on its way to becoming a global marketing services industry leader. He has also held executive positions at Experian, TRW, and Dun and Bradstreet.
Laben is an active investor, board member, and advisor to numerous companies and organizations.
About Trax Retail
Trax’s mission is to enable brands and retailers to harness the power of digital technologies to produce the best shopping experiences imaginable. Trax’s retail platform allows customers to understand and improve what is happening on the shelf, in every store, all the time so they can focus on what they do best – delighting shoppers.
Many of the world’s top CPG companies, emerging brands, and retail leaders use Trax’s shelf monitoring, analytics, merchandising, activation, and shopper engagement solutions at scale to drive positive shopper experiences and unlock revenue opportunities at all points of sale.
As pioneers in computer vision, Trax continues to lead the industry in innovation and excellence through the development of artificial intelligence-powered solutions, autonomous data collection methods, and on-demand merchandising capabilities. Trax is a global company with hubs in the United States, Singapore, Hungary, Beijing, Mexico and Israel, serving customers in more than 90 countries worldwide. To learn more, visit www.traxretail.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240311108646/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
